Is a complete BIOA research report available?

No complete published report is available for BioAge Labs, Inc. (BIOA) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

BioAge Labs, Inc. (BIOA)

NASDAQ: BIOA · USD

$5.95

+0.47 (+8.7%)· Recorded snapshot

Market cap	272.9M
Revenue (ttm)	10.4M
Net income (ttm)	-94.5M
EPS (ttm)	-$2.37
Shares out	45.9M
Volume	1,311,988
Beta	1.08

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 10.4M
Net income (ttm): -94.5M
EPS (ttm): -$2.37
Market cap: 272.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	نگه‌داری

Metric	Value
Amount currency	USD
CIK code	0001709941
Company name	BioAge Labs, Inc.
Country	United States
Country code	US
CUSIP number	09077V100
Earnings date	2026-11-09
Earnings time	amc
Employees	62
Employees change	-2
Employees growth	-3.13%
Enterprise value	$-105.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Founded	2015
In index	RUSSELL2000
Industry	Drug Manufacturers - Specialty & Generic
IPO date	2024-09-26
Is primary listing	Yes
Is SPAC	No
ISIN number	US09077V1008
Last 10-K release date	2026-03-24
Last earnings date	2026-08-05
Last refreshed	2026-10-28
Last stock split type	Never
Market cap	$272.9M
Market cap category	Micro-Cap
Next earnings date	2026-11-09
Options	Yes
Price	$5.95
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	BIOA
Tags	weight-loss
U.S. state	California
Website	https://bioagelabs.com

Metric

Value

Amount currency

USD

CIK code

0001709941

Company name

BioAge Labs, Inc.

Country

United States

Country code

CUSIP number

09077V100

Earnings date

2026-11-09

Earnings time

amc

Employees

Employees change

-2

Employees growth

-3.13%

Enterprise value

$-105.6M

Exchange

NASDAQ

Financial currency

USD

Financial report date

2026-06-30

First seen

2026-05-09

Fiscal year end

December

Founded

2015

In index

RUSSELL2000

Industry

Drug Manufacturers - Specialty & Generic

IPO date

2024-09-26

Is primary listing

Yes

Is SPAC

ISIN number

US09077V1008

Last 10-K release date

2026-03-24

Last earnings date

2026-08-05

Last refreshed

2026-10-28

Last stock split type

Never

Market cap

$272.9M

Market cap category

Micro-Cap

Next earnings date

2026-11-09

Options

Yes

Price

$5.95

Price currency

USD

Sector

Healthcare

SIC code

2834

Stock price date

2026-10-28

Symbol

BIOA

Tags

weight-loss

U.S. state

California

Website

https://bioagelabs.com

Metric	Value
Earnings yield	-39.88%
FCF / EV yield	77.86%
FCF yield	-33.21%
Forward P/S	87.09x
Industry forward P/E	13.59x
Industry P/E	175.96x
P/B ratio	0.67x
P/S ratio	25.62x
Price / tangible book value	0.71x
Sector forward P/E	23.56x
Sector P/E	50.13x

Metric

Value

Earnings yield

-39.88%

FCF / EV yield

77.86%

FCF yield

-33.21%

Forward P/S

87.09x

Industry forward P/E

13.59x

Industry P/E

175.96x

P/B ratio

0.67x

P/S ratio

25.62x

Price / tangible book value

0.71x

Sector forward P/E

23.56x

Sector P/E

50.13x

Metric	Value
Operating margin	-1,026.28%
Pretax margin	-912.25%
Profit per employee	$-1.5M
Revenue per employee	$167,016
ROA	-18.47%
ROCE	-28.14%
ROE	-28.21%
ROIC	-19.5%
SBC / revenue	135.57%

Metric

Value

Operating margin

-1,026.28%

Pretax margin

-912.25%

Profit per employee

$-1.5M

Revenue per employee

$167,016

ROA

-18.47%

ROCE

-28.14%

ROE

-28.21%

ROIC

-19.5%

SBC / revenue

135.57%

Metric	Value
EPS growth quarters	1
EPS growth years	2
Net income growth years	0
Revenue growth	168.06%
Revenue growth (Q)	1.62%
Revenue growth (QoQ)	-11.58%
Revenue growth quarters	2
Revenue growth years	0

Metric

Value

EPS growth quarters

EPS growth years

Net income growth years

Revenue growth

168.06%

Revenue growth (Q)

1.62%

Revenue growth (QoQ)

-11.58%

Revenue growth quarters

Revenue growth years

Metric	Value
Capital expenditures	$-488,000
Depreciation and amortization	$251,000
EBIT	$-106.3M
EBITDA	$-106M
EPS	$-2.37
FCF per share	$-1.92
Financing cash flow	$154.2M
Free cash flow	$-88.1M
Free cash flow minus SBC	$-102.1M
Gross profit	$-77.4M
Investing cash flow	$-212.9M
Net borrowing	$-5M
Net cash flow	$-146.4M
Net income	$-94.5M
Operating cash flow minus SBC	$-101.6M
Operating income	$-106.3M
Revenue	$10.4M
Stock-based compensation	$14M

Metric

Value

Capital expenditures

$-488,000

Depreciation and amortization

$251,000

EBIT

$-106.3M

EBITDA

$-106M

EPS

$-2.37

FCF per share

$-1.92

Financing cash flow

$154.2M

Free cash flow

$-88.1M

Free cash flow minus SBC

$-102.1M

Gross profit

$-77.4M

Investing cash flow

$-212.9M

Net borrowing

$-5M

Net cash flow

$-146.4M

Net income

$-94.5M

Operating cash flow minus SBC

$-101.6M

Operating income

$-106.3M

Revenue

$10.4M

Stock-based compensation

$14M

Metric	Value
Altman Z-Score	12.72
Book value per share	$8.19
Debt / equity	0.01
Interest coverage	-378.19
Long-term assets	$66.6M
Long-term liabilities	$2.8M
Net cash (debt)	$378.4M
Net cash / market cap	142.65%
Net cash growth	24.21%
Net debt / equity	-1.01
Piotroski F-Score	4
Property, plant and equipment	$3.8M
Shareholders' equity	$374.9M
Tangible book value	$374.9M
Tangible book value per share	$8.19
Total assets	$396.9M
Total cash	$318.7M
Total debt	$2.8M
Total liabilities	$22M
WACC	10.17%

Metric

Value

Altman Z-Score

12.72

Book value per share

$8.19

Debt / equity

0.01

Interest coverage

-378.19

Long-term assets

$66.6M

Long-term liabilities

$2.8M

Net cash (debt)

$378.4M

Net cash / market cap

142.65%

Net cash growth

24.21%

Net debt / equity

-1.01

Piotroski F-Score

Property, plant and equipment

$3.8M

Shareholders' equity

$374.9M

Tangible book value

$374.9M

Tangible book value per share

$8.19

Total assets

$396.9M

Total cash

$318.7M

Total debt

$2.8M

Total liabilities

$22M

WACC

10.17%

Metric	Value
Asset turnover	0.03
Current assets	$330.3M
Current liabilities	$19.2M
Current ratio	17.19
Net working capital	$-6.9M
Quick ratio	16.75
Working capital	$311.1M
Working capital turnover	0.04

Metric

Value

Asset turnover

0.03

Current assets

$330.3M

Current liabilities

$19.2M

Current ratio

17.19

Net working capital

$-6.9M

Quick ratio

16.75

Working capital

$311.1M

Working capital turnover

0.04

Metric	Value
Buyback yield / dilution	-43.29%
Dividend yield	0%
Shareholder yield	-43.29%

Metric

Value

Buyback yield / dilution

-43.29%

Dividend yield

Shareholder yield

-43.29%

Metric	Value
150-day SMA	$14.58
1D price change	8.68%
1M price change	-17.45%
1M total return	-17.45%
1W price change	4.68%
1W total return	4.68%
1Y price change	-23.72%
1Y return CAGR	-23.74%
1Y total return	-23.72%
20-day SMA	$5.75
200-day SMA	$15.98
3M price change	-72.13%
3M total return	-72.13%
50-day SMA	$7.56
50-day SMA vs 200-day SMA	50under200
52-week high	$25.96
52-week high date	2026-07-06
52-week low	$4.81
52-week low date	2026-10-16
6M price change	-67.77%
6M total return	-67.77%
All-time high	$26.62
All-time high date	2024-10-22
All-time low	$2.88
All-time low date	2025-04-09
Average true range (ATR)	$0.46
Average volume	896.8K
Beta (1Y)	2.2
Beta (2Y)	1.81
Beta (5Y)	1.08
Change from 52-week high	-77.09%
Change from 52-week low	23.6%
Change from all-time high	-78.14%
Change from all-time low	102.08%
Change from open	10.91%
Day's gap	-2.01%
Dollar volume	$7.8M
High price	$5.95
Low price	$5.36
Monthly RSI	38.4
Open price	$5.36
Position in 52-week range	99.15%
Premarket change	11.15%
Premarket close	$5.47
Premarket price	$6.08
Premarket volume	665
Previous close	$5.47
Price vs 150-day SMA	-60.09%
Price vs 20-day SMA	1.24%
Price vs 200-day SMA	-63.57%
Price vs 50-day SMA	-23.05%
Relative volume	1.46
Return from IPO open	-74.31%
Return from IPO price	-67.89%
RSI	42.51
Sharpe ratio	0.38
Sortino ratio	0.55
Volume	1.3M
Weekly RSI	34.75
YTD price change	-56.01%
YTD total return	-56.01%

Metric

Value

150-day SMA

$14.58

1D price change

8.68%

1M price change

-17.45%

1M total return

-17.45%

1W price change

4.68%

1W total return

4.68%

1Y price change

-23.72%

1Y return CAGR

-23.74%

1Y total return

-23.72%

20-day SMA

$5.75

200-day SMA

$15.98

3M price change

-72.13%

3M total return

-72.13%

50-day SMA

$7.56

50-day SMA vs 200-day SMA

50under200

52-week high

$25.96

52-week high date

2026-07-06

52-week low

$4.81

52-week low date

2026-10-16

6M price change

-67.77%

6M total return

-67.77%

All-time high

$26.62

All-time high date

2024-10-22

All-time low

$2.88

All-time low date

2025-04-09

Average true range (ATR)

$0.46

Average volume

896.8K

Beta (1Y)

2.2

Beta (2Y)

1.81

Beta (5Y)

1.08

Change from 52-week high

-77.09%

Change from 52-week low

23.6%

Change from all-time high

-78.14%

Change from all-time low

102.08%

Change from open

10.91%

Day's gap

-2.01%

Dollar volume

$7.8M

High price

$5.95

Low price

$5.36

Monthly RSI

38.4

Open price

$5.36

Position in 52-week range

99.15%

Premarket change

11.15%

Premarket close

$5.47

Premarket price

$6.08

Premarket volume

665

Previous close

$5.47

Price vs 150-day SMA

-60.09%

Price vs 20-day SMA

1.24%

Price vs 200-day SMA

-63.57%

Price vs 50-day SMA

-23.05%

Relative volume

1.46

Return from IPO open

-74.31%

Return from IPO price

-67.89%

RSI

42.51

Sharpe ratio

0.38

Sortino ratio

0.55

Volume

1.3M

Weekly RSI

34.75

YTD price change

-56.01%

YTD total return

-56.01%

Metric	Value
Float	39.2M
Float percentage	85.39%
Shares change (QoQ)	5.55%
Shares change (YoY)	43.29%
Shares held by insiders	2.36%
Shares held by institutions	76.93%
Shares outstanding	45.9M
Short % of float	8.76%
Short % of shares	7.48%
Short ratio	4.7 days

Metric

Value

Float

39.2M

Float percentage

85.39%

Shares change (QoQ)

5.55%

Shares change (YoY)

43.29%

Shares held by insiders

2.36%

Shares held by institutions

76.93%

Shares outstanding

45.9M

Short % of float

8.76%

Short % of shares

7.48%

Short ratio

4.7 days

BioAge Labs, Inc. (BIOA)

Price

Financial snapshot

Fair-value bridge

Latest news · BIOA

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All BIOA indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on BIOA

Frequently asked questions